Cargando…

Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus

OBJECTIVE: Childhood‐onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long‐term outcome data are limited. This study was undertaken to identify clinical characteristics and health‐related quality of life (HRQoL) of adults with childhood‐onset SLE. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Groot, N., Shaikhani, D., Teng, Y. K. O., de Leeuw, K., Bijl, M., Dolhain, R. J. E. M., Zirkzee, E., Fritsch‐Stork, R., Bultink, I. E. M., Kamphuis, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590133/
https://www.ncbi.nlm.nih.gov/pubmed/30152151
http://dx.doi.org/10.1002/art.40697
_version_ 1783429491685588992
author Groot, N.
Shaikhani, D.
Teng, Y. K. O.
de Leeuw, K.
Bijl, M.
Dolhain, R. J. E. M.
Zirkzee, E.
Fritsch‐Stork, R.
Bultink, I. E. M.
Kamphuis, S.
author_facet Groot, N.
Shaikhani, D.
Teng, Y. K. O.
de Leeuw, K.
Bijl, M.
Dolhain, R. J. E. M.
Zirkzee, E.
Fritsch‐Stork, R.
Bultink, I. E. M.
Kamphuis, S.
author_sort Groot, N.
collection PubMed
description OBJECTIVE: Childhood‐onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long‐term outcome data are limited. This study was undertaken to identify clinical characteristics and health‐related quality of life (HRQoL) of adults with childhood‐onset SLE. METHODS: Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI‐2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed. RESULTS: In total, 111 childhood‐onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI‐2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease‐modifying antirheumatic drugs. The vast majority of new childhood‐onset SLE–related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI‐2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively). CONCLUSION: The majority of adults with childhood‐onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug‐free remission, illustrating the substantial impact of childhood‐onset SLE on future life.
format Online
Article
Text
id pubmed-6590133
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65901332019-07-08 Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus Groot, N. Shaikhani, D. Teng, Y. K. O. de Leeuw, K. Bijl, M. Dolhain, R. J. E. M. Zirkzee, E. Fritsch‐Stork, R. Bultink, I. E. M. Kamphuis, S. Arthritis Rheumatol Systemic Lupus Erythematosus OBJECTIVE: Childhood‐onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long‐term outcome data are limited. This study was undertaken to identify clinical characteristics and health‐related quality of life (HRQoL) of adults with childhood‐onset SLE. METHODS: Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI‐2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed. RESULTS: In total, 111 childhood‐onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI‐2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease‐modifying antirheumatic drugs. The vast majority of new childhood‐onset SLE–related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI‐2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively). CONCLUSION: The majority of adults with childhood‐onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug‐free remission, illustrating the substantial impact of childhood‐onset SLE on future life. John Wiley and Sons Inc. 2019-01-29 2019-02 /pmc/articles/PMC6590133/ /pubmed/30152151 http://dx.doi.org/10.1002/art.40697 Text en © 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Systemic Lupus Erythematosus
Groot, N.
Shaikhani, D.
Teng, Y. K. O.
de Leeuw, K.
Bijl, M.
Dolhain, R. J. E. M.
Zirkzee, E.
Fritsch‐Stork, R.
Bultink, I. E. M.
Kamphuis, S.
Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title_full Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title_fullStr Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title_full_unstemmed Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title_short Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
title_sort long‐term clinical outcomes in a cohort of adults with childhood‐onset systemic lupus erythematosus
topic Systemic Lupus Erythematosus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590133/
https://www.ncbi.nlm.nih.gov/pubmed/30152151
http://dx.doi.org/10.1002/art.40697
work_keys_str_mv AT grootn longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT shaikhanid longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT tengyko longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT deleeuwk longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT bijlm longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT dolhainrjem longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT zirkzeee longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT fritschstorkr longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT bultinkiem longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus
AT kamphuiss longtermclinicaloutcomesinacohortofadultswithchildhoodonsetsystemiclupuserythematosus